2013 Shaffer Research Grants

For information about Shaffer Grants and research reports prior to 2013, please contact Glaucoma Research Foundation.

Spacing: small

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

Spacing: small
Anneke Den Hollander

Anneke I. den Hollander, PhD

Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Funded by The Dr. Miriam Yelsky Memorial Research Grant
Project: Dissecting the Genetic Causes of Congenital and Juvenile Glaucoma
Summary: Glaucoma is a leading cause of irreversible blindness affecting 70 million people worldwide.
John H. Fingert

John H. Fingert, MD, PhD

University of Iowa, Department of Ophthalmology and Visual Sciences, Iowa City, Iowa
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Molecular Genetic Study of Normal Tension Glaucoma using Transgenic Mice
Summary: There is a critical need to clarify the mechanisms of glaucoma at the molecular level to help provide physicians with tools for early detection and treatment.
M. Elizabeth Fini, Phd

M. Elizabeth Fini, PhD

University of Southern California, Institute for Genetic Medicine, Los Angeles, California
Funded by the Merck Department of Continuing Education
Project: Novel Mucins and Aqueous Outflow
Summary: The idea that mucins might be present in this lining layer and play a role in OH has not been previously considered. If confirmed, the findings will open a new line of research that could ultimately lead to significant innovation, as drugs that control amounts of the novel mucins could be a new treatment paradigm for glaucoma.
Andras Komaromy

Andras M. Komaromy, DrMedVet, PhD

Michigan State University, East Lansing, Michigan
Funded by The Alcon Foundation
Project: Gene Therapy in a Spontaneous Canine Model of Primary Open-Angle Glaucoma
Summary: Primary open-angle glaucoma (POAG) is a leading cause of incurable blindness. Increased pressure inside the eye due to slowed fluid drainage contributes to the disease process in a majority of patients with POAG.
Colleen Mcdowell

Colleen M. McDowell, PhD

University of North Texas Health Science Center, Fort Worth, Texas
Funded by The Alcon Foundation
Project: Retina Ganglion Cell Subtype Specific Cell Death in a Mouse Model of Human Primary Open-Angle Glaucoma
Summary: The goal of this project is to better understand the mechanisms involved in glaucomatous injury to the eye.
Yvonne Ou, Md

Yvonne Ou, MD

University of California San Francisco, Department of Ophthalmology, San Francisco, California
Funded by the Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Investigating Axonal Death Pathways in Glaucoma
Summary: A major deficit in glaucoma management is that a diagnosis is made or treatment is initiated after there is already evidence of optic nerve cell death or visual field loss. Our goal is to investigate the parts of the optic nerve cell, specifically axons and synapses, which may be vulnerable early in the course of the disease.
David Sretavan

David Sretavan, MD, PhD

University of California San Francisco, San Francisco, California
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Pathophysiological Progression in Single RGC Axons Following Microscale Compressive Injury
Summary: The debilitating loss of vision associated with advanced forms of glaucoma result directly from the degeneration of Retinal Ganglion Cells (RGC) in the retina.
Lin Wang

Lin Wang, MD, PhD

Devers Eye Institute/Legacy Research Institute, Portland, Oregon
Funded by The Alcon Foundation
Project: Noninvasive Assessment of Dynamic Autoregulation in Optic Nerve Head
Summary: Glaucoma is one of the leading causes of blindness worldwide characterized by irreversible damage in the optic nerve head (ONH).